News & Events

  • 05 May 2017
  • Hetero receives generic Sofosbuvir+Velpatasvir approval for India
  • India, Hyderabad, 5th May, 2017: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that it has received the approval for the generic version of ’Sofosbuvir+Velpatasvir’ combination from Drugs Controller General of India. Read more
  • 02 Jul 2016
  • Hetero launches Biosimilar Bevacizumab
  • Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'CizumabTM' Read more